Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053987 | 1.00 | MMP2 (0.39) | MMP2MMP1MMP3MMP7MMP13 | |
| Hydrochloric Acid SCHEMBL873472 | 0.98 | MMP2 (0.38) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL8706642 | 0.98 | MMP2 (0.41) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL1273086 | 0.98 | MMP2 (0.41) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL22303144 | 0.98 | MMP2 (0.41) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL24946223 | 0.98 | MMP2 (0.41) | MMP2MMP1MMP3MMP7MMP13 | |
| Hydrochloric Acid SCHEMBL1021562 | 0.96 | MMP2 (0.40) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL24964865 | 0.95 | MMP2 (0.36) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL24964866 | 0.95 | MMP2 (0.36) | MMP2MMP1MMP3MMP7MMP13 | |
| SCHEMBL23361004 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250129398-A1 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-24 | — | — | US | disclosed |
| EP-4520748-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-12 | — | — | EP | disclosed |
| CN-119156373-A | Method for producing salts of amino acids or salts of peptide compounds or solvates of any of the salts comprising a lithium salt precipitation step | 中外制药株式会社 | 2024-12-17 | — | — | CN | disclosed |
| CN-118401654-A | Polypeptide and method for preparing amino acid using same | 中外制药株式会社 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023219152-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | 中外製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023127752-A1 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | 中外製薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| EP-4206322-A2 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-07-05 | — | — | EP | disclosed |
| EP-4206322-A2 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| EP-3159345-A1 | INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-6982082-B1 | Gene therapy by cell specific targeting | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-03 | — | — | US | disclosed |
| EP-0939822-A2 | USE OF MUTATED MACROLIDE BINDING PROTEIN FOR THE PREVENTION OF GUHD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998008956-A2 | USE OF A MUTATED MACROLIDE BINDING PROTEIN FOR THE PREVENTION OF GVHD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368680-A1 | METHOD FOR PRODUCING SALT OF AMINO ACID OR SALT OF PEPTIDE COMPOUND OR SOLVATE OF EITHER ONE OF SAID SALTS COMPRISING LITHIUM SALT PRECIPITATION STEP | NPPA, DNPEP, NPEPPS | MMP2 1482/4885MMP1 1760/4885MMP3 1512/4885 |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | MMP2 2333/4885MMP1 3245/4885MMP3 1925/4885 |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | MMP2 165/4885MMP1 1270/4885MMP3 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.